Johnson & Johnson (JNJ)

NYQ – Real Time Price. Currency in USD

268.79

+11.01 (4.27%)

Market open: Oct 22, 2026, 2:45 PM EDT

21.10.2026

Johnson & Johnson Raised Its Dividend Every Year. Why Did It Trail the S&P 500?

Johnson and Johnson has raised its dividend every single year for 64 years straight, yet a plain S&P 500 index fund still beat it handily over the past decade.

21.10.2026

3 of the Best Value Stocks to Own

#StockstoBuy #ValueStocks #TheMorningFilter These value stocks with wide economic moats are good long-term investments when you can buy them at a discount.

21.10.2026

Is Most-Watched Stock Johnson & Johnson (JNJ) Worth Betting on Now?

Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

21.10.2026

Johnson & Johnson's Profit Fell 96% Year-Over-Year. But the Dividend Has Risen for 64 Years in a Row

Johnson and Johnson just posted a 96% profit collapse, yet on the same day raised its full-year guidance and extended a dividend streak most companies only dream about.

20.10.2026

Healthcare ETFs to Buy as JNJ Slips 6% Despite Q3 Earnings Beat

Johnson & Johnson's Q3 earnings beat fails to prevent a 6% stock drop, but three healthcare ETFs offer diversified exposure to its growth potential.

20.10.2026

Johnson & Johnson Launches Next-Generation Shockwave™ C2 Aero Fly Coronary IVL Catheter, Cutting IVL Treatment Time in Half

SANTA CLARA, Calif.--(BUSINESS WIRE)--Next-generation IVL catheter delivers pulses at 2 Hz, improving efficiency in calcium modification treatment of coronary artery disease.

20.10.2026

Johnson & Johnson to Showcase the Future of Surgical Intelligence at Abu Dhabi Future Health Summit 2026

ABU DHABI, United Arab Emirates--(BUSINESS WIRE)-- #PressRelease--Johnson & Johnson will showcase digital surgery technologies and its Department of Health - Abu Dhabi collaboration at the Future Health Summit 2026.

Videos

21.10.2026

Positive

3 of the Best Value Stocks to Own

14.10.2026

Negative

Johnson & Johnson shares SLIDE nearly 6% despite stronger full-year forecast

13.10.2026

Positive

J&J raises its forecast again. CFO Joe Wolk on what's driving it

13.10.2026

Negative

Johnson & Johnson shares fall following earnings

Upgrades / Downgrades

Ticker	Brokerage Firm	Ratings Change	Price Target	Date
JNJ	Erste Group	Hold	undefined >> undefined	October 21st 2026
JNJ	UBS	Buy	undefined >> $320	September 2nd 2026

Press releases

20.10.2026

Johnson & Johnson Launches Next-Generation Shockwave™ C2 Aero Fly Coronary IVL Catheter, Cutting IVL Treatment Time in Half

SANTA CLARA, Calif.--(BUSINESS WIRE)--Next-generation IVL catheter delivers pulses at 2 Hz, improving efficiency in calcium modification treatment of coronary artery disease.

20.10.2026

Johnson & Johnson to Showcase the Future of Surgical Intelligence at Abu Dhabi Future Health Summit 2026

19.10.2026

Johnson & Johnson announces new data showing TREMFYA® (guselkumab) is the only IL-23 to deliver durable fistula remission through 48 weeks in Crohn's disease with perianal fistula

TREMFYA maintained combined fistula remission through Week 48 across both maintenance dose regimens, including an increase from 28% at Week 24 to 35% at Week 48 in the 100 mg dose group These findings build on the Phase 3 clinical program, demonstrating efficacy in a dedicated, randomized, placebo-controlled trial in patients with this debilitating and challenging manifestation of Crohn's disease SPRING HOUSE, Pa., Oct. 19, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced one-year results from the Phase 3 FUZION study showing TREMFYA® (guselkumab) maintained or improved fistula remission through 48 weeks in adults with Crohn's disease (CD).1 The findings build on the previously reported Week 24 results and further support the use of TREMFYA in one of the most difficult-to-treat manifestations of CD 2.

18.10.2026

JNJ Investors with $100,000 in Losses Have Opportunity to Join Johnson & Johnson Fraud Investigation with SBS Law

LOS ANGELES--(BUSINESS WIRE)---- $JNJ--JNJ Investors with $100,000 in Losses Have Opportunity to Join Johnson & Johnson Fraud Investigation with SBS Law.

Johnson & Johnson (JNJ)

Get all premium features to the best stock analysis tool

Finranks

Contact us

Follow us

Johnson & Johnson (JNJ)